| Name | Title | Contact Details |
|---|
biBerk helps small-business owners find the right insurance policies for their needs without extra costs and hassles. As a part of Warren Buffetts Berkshire Hathaway insurance group, our approach is to help you find the coverage thats right for your business right now. As your business grows, we offer the added insurance products that you need so your coverage grows with you. biBerk can help you with all your small business insurance needs, including: - Workers Compensation - Professional Liability (E&O) - General Liability - Property & Liability (BOP) - Commercial Auto - Umbrella Were also backed by an expert customer service team that can answer any question you throw at them. Well help you find the right insurance policy for your small business. Rated A++ by A.M. Best Company and AAA by Standard & Poors Corporation
The Louis D. Brandeis Center, Inc. (LDB) is an independent, non-partisan institution for public interest advocacy, research and education. The Centers mission is to advance the civil and human rights of the Jewish people and to promote justice for all.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.